Skip to main content

Proteinuria

2
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
valsartanPhase 4Small Molecule1 trial
Active Trials
NCT00241085Completed392Est. Aug 2005
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ALXN1720Phase 11 trial
Active Trials
NCT05314231Completed13Est. May 2023
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
TCM+ Routine TherapyN/A1 trial
Active Trials
NCT05759754Completed72Est. Dec 2024
Bristol Myers Squibb
1 program
BelataceptPHASE_21 trial
Active Trials
NCT02327403Completed15Est. Oct 2020
Travere Therapeutics
1 program
SparsentanPHASE_41 trial
Active Trials
NCT07219121Recruiting20Est. May 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Travere TherapeuticsSparsentan
Sandozvalsartan
Bristol Myers SquibbBelatacept
AstraZenecaALXN1720
UNION therapeuticsTCM+ Routine Therapy

Clinical Trials (5)

Total enrollment: 512 patients across 5 trials

NCT07219121Travere TherapeuticsSparsentan

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Start: Oct 2025Est. completion: May 202720 patients
Phase 4Recruiting
NCT00241085Sandozvalsartan

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Start: Nov 2002Est. completion: Aug 2005392 patients
Phase 4Completed
NCT02327403Bristol Myers SquibbBelatacept

Belatacept Conversion in Proteinuric Kidney Transplant Recipients

Start: Oct 2015Est. completion: Oct 202015 patients
Phase 2Completed
NCT05314231AstraZenecaALXN1720

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Start: Jun 2022Est. completion: May 202313 patients
Phase 1Completed
NCT05759754UNION therapeuticsTCM+ Routine Therapy

Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease

Start: Sep 2023Est. completion: Dec 202472 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 512 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.